Answers are grounded in this paper and cite their sources.
Gene therapy is defined as the ability to change individual's genetics by correcting genetic mutations or making site-specific alterations that target therapeutic treatment. The focus of gene therapy is optimization of delivery vectors. Peptide-based DNA delivery vaccine is a field in non-viral gene delivery systems and not many researchers have looked after it. DNA vaccines have many appealing production potentials, including the ability to provide cross-protection against various virus subtypes, mass manufacturing in a reasonably short period, and greater stability than other delivery systems. Non-viral approaches are considered benign than viral delivery because of factors such as lack of immunogenicity , low toxicity, and the potential for tissue specificity. DNA vaccines have several limitations but, in this review, we focus on how a novel peptide R9-K-GALA can be used in DNA vaccine and overcome almost all the pitfalls. It is also expected that this delivery system can be used to protect against Malaria. R9-K-GALA is a novel peptide, and arginine (R) is used in this peptide because GALA cannot directly bind to DNA. So, Arginine will help to bind DNA as arginine being positively charged and DNA is negatively charged. This review mainly focuses on how peptides can be used to make DNA vaccines and how DNA vaccines in the coming future can be a breakthrough for many diseases.
No takes yet. Share an insight, caveat, or question.
Somvanshi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: